Introduction: Gastric carcinogenesis is a multistep process including mutation of different genes as well as epigenetic events as aberrant promotor methylation leading to gene silencing. Morphologically, disease progression appears as a sequence of intestinal metaplasia -dysplasia -invasive carcinoma, triggered by Helicobacter pylori (HP) infection. Methylation of the Estrogen receptor (ER) promotor has been attributed to the development of colorectal cancer and esophageal adenocarcinoma. Its role in gastric carcinogenesis has remained so far elusive. Methods: To study Estrogen promotor methylation patterns along the carcinogenesis pathway in the stomach, we examined gastric mucosa in different conditions by qunatitative methylation specific PCR (rt-MSP). We tested samples from 8 newborns, 49 individuals who underwent endoscopy due to dyspepsia and 8 cases with intestinal metaplasia, as well as from 30 individuals with gastric cancer. PCR specimen were analysed blind and later correlated with histopathological findings. Results: None of the 8 newborns showed a positive rt-MSP results. From the 49 individuals examined, 27 had histologically normal gastric mucosa (13/49) or Helicobacter pylori negative gastritis (14/49). Three specimen of this population showed positive rt-MSP results (11%). On the other hand all individuals with H. pylori positive gastritis (22/49) showed ER promotor methylation (100%). Furthermore, 8 specimen from gastric intestinal metaplasia and 30 samples from gastric cancer tested positive for ER promotor methylation. The correleation of ER promotor methylation with H. pylori gastritis, intestinal metaplasia and gastric carcinoma was highly significant. Discussion: ER promoter methylation has been reported in the context of esophageal and colon carcinogenesis. Here we demonstrate that this epigenetic event is not tumor specific but already present in precancerous lesions of gastric cancer, as early as HP positive gastritis. This data suggest that ER promoter methylation might play a role in the early steps of gastric carcinogenesis and possibly can identify individuals at risk for this highly prevalent tumor.
Introduction: Gastric carcinogenesis is a multistep process including mutation of different genes as well as epigenetic events as aberrant promotor methylation leading to gene silencing. Morphologically, disease progression appears as a sequence of intestinal metaplasia -dysplasia -invasive carcinoma, triggered by Helicobacter pylori (HP) infection. Methylation of the Estrogen receptor (ER) promotor has been attributed to the development of colorectal cancer and esophageal adenocarcinoma. Its role in gastric carcinogenesis has remained so far elusive. Methods: To study Estrogen promotor methylation patterns along the carcinogenesis pathway in the stomach, we examined gastric mucosa in different conditions by qunatitative methylation specific PCR (rt-MSP). We tested samples from 8 newborns, 49 individuals who underwent endoscopy due to dyspepsia and 8 cases with intestinal metaplasia, as well as from 30 individuals with gastric cancer. PCR specimen were analysed blind and later correlated with histopathological findings. Results: None of the 8 newborns showed a positive rt-MSP results. From the 49 individuals examined, 27 had histologically normal gastric mucosa (13/49) or Helicobacter pylori negative gastritis (14/49). Three specimen of this population showed positive rt-MSP results (11%). On the other hand all individuals with H. pylori positive gastritis (22/49) showed ER promotor methylation (100%). Furthermore, 8 specimen from gastric intestinal metaplasia and 30 samples from gastric cancer tested positive for ER promotor methylation. The correleation of ER promotor methylation with H. pylori gastritis, intestinal metaplasia and gastric carcinoma was highly significant. Discussion: ER promoter methylation has been reported in the context of esophageal and colon carcinogenesis. Here we demonstrate that this epigenetic event is not tumor specific but already present in precancerous lesions of gastric cancer, as early as HP positive gastritis. This data suggest that ER promoter methylation might play a role in the early steps of gastric carcinogenesis and possibly can identify individuals at risk for this highly prevalent tumor. Adjusted OR for gastric cancer increased 3-fold for subjects reporting first degree relatives with gastric cancer (OR 2.85, 95% CI: 1.83-4.46). The association was strong in the 40 -59 age group (OR 4.00, 95% CI: 2.06-7.76), and became weaker in subjects older than 60 years of age (OR 1.81, 95% CI: 0.95-3.46). Compared to the uninfected subjects without a family history, subjects with both a family history and H. pylori infection had a 5-fold increased risk (OR 5.32, 95% CI: 2.76-10.25). Conclusions: After adjusting for environmental factors and H. pylori infection, a family history of gastric cancer remained independently associated with gastric cancer. The interaction between H. pylori infection and family history of gastric cancer might be a rationale for H. pylori eradication in the gastric cancer relatives as a strategy to prevent gastric cancer. Intestinal metaplasia (IM) of the stomach is associated with an increased risk of gastric carcinoma and consists in the transdifferentiation of gastric epithelial cells to an intestinal phenotype. The intestinal differentiation, both in normal and aberrant locations, is dependent on the presence of the homeobox gene CDX2. In normal conditions CDX2 is only expressed in the adult intestine but several studies, including our own, have shown that CDX2 is strongly expressed in human intestinal metaplastic lesions of the stomach, oesophagus, liver and gallbladder. Moreover, it was shown in a mouse model that CDX2 expression in the stomach was sufficient for the development of IM. The molecular mechanisms that regulate CDX2 expression are yet mostly unknown. We have recently shown that elements of the BMP/ SMAD4 pathway not only co-localize with CDX2 in IM but also regulate CDX2 expression in gastric cell lines. Furthermore, it has been reported that CDX2 transactivates its own promoter In Vitro. The autoregulatory mechanism could be very important in IM establishment and maintenance hence we studied the putative regulation of CDX2 expression by the CDX2 protein. We show that CDX2 is able to transactivate a 9,3kb fragment of the mCdx2 promoter, to different extents, in a panel of both gastric and intestinal cell lines, using Luciferase assays. Further, we demonstrate that CDX2 is bound to at least 3 different sites on its proximal 1,7kb promoter in a living gastric carcinoma cell line. Finally, when transfecting cell lines with an exogenous CDX2-expressing vector, we found increased expression of its endogenous counterpart, and inclusively an activation of its expression in HeLa cell line, which does not express CDX2. Altogether, this results show that CDX2 is able, in fact, to autoregulate its expression In Vitro. Further studies are needed to elucidate if this regulatory pathway may be important In Vivo as well. Patients involving the entire stomach were excluded (169 patients). The clinicopathologic parameters along with respective survival data were analyzed comparing findings in patients with PGC and those with middle or distal gastric carcinoma (DGC). Results Chronological analysis showed increasing incidence of PGC over the study period. PGC patients were younger and Bormann type III & IV were more common than DGC patients. Also, PGC patients were significantly associated with higher proportion of poorly differentiated type, T3 & T4 stage, positive lymph node compared to DGC patients. Pattern of metastasis of AGC was different according to the location. Peritoneal and other distant metastasis were significantly higher in PGC group compared to DGC group. The 5 year survival rate for PGC was 59.6% and that of DGC was 73.7% (p<0.001). In curatively resected patients, the 5-year survival rate was significantly lower in PGC than DGC. Also N0 and N1 category significantly influenced the 5 year survival rate. TNM stage, hepatic metastasis and curative resection were the significant prognostic factors in PGC patients. Conclusions PGC is increasing in incidence with respective decline in H. pylori prevalence in Korea. The five year survival was worse for patients with PGC than for those with DGC regardless of curative respectability. PGC is diagnosed in more advanced stages and special attention should be warranted for early detection.
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